Loading
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.
Previous close
$28.23
+$0.31 · +1.11%
Regular session · ET · Market data may be delayed.
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.
Day range
Current $28.23
52-week range
Current $28.23
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
40
Expensive
Sentiment
62
Bullish
Risk
50
Elevated Risk
Momentum
63
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.
Day range
Current $28.23
52-week range
Current $28.23
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 335K USD | — | — | — | — |
| Gross profit | −335K USD | — | — | — | — |
| Research and development | 38.73M USD | 35.02M USD | 29.82M USD | 20.48M USD | 8.55M USD |
| Selling, general, and administrative | 21.61M USD | 15M USD | 11.12M USD | 10.06M USD | 6.54M USD |
| Operating expenses | 60.34M USD | 50.31M USD | 41.22M USD | 30.55M USD | 15.1M USD |
| Interest income | 2.63M USD | 2.63M USD | 1.89M USD | 858K USD | 9 USD |
| Interest expense | 463K USD | 717K USD | 723K USD | — | 9K USD |
| Depreciation and amortization | 335K USD | 315K USD | 315K USD | 47K USD | 19K USD |
| Operating income | −60.68M USD | −50.31M USD | −41.22M USD | −30.55M USD | −15.1M USD |
| Net income | −48.26M USD | −38.96M USD | −35.59M USD | −22.46M USD | −9.2M USD |
Company facts updated Sep 7, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$48.83
72.97% upsideFunds reporting this stock among their holdings, ordered by reported position size.
iShares Biotechnology ETFIBB10.34M0.10%10.73B USD0.44%$211.92-0.88%
AdvisorShares Psychedelics ETFPSIL2.54M4.58%55.79M USD1.84%$24.86+1.10%
iShares MSCI Ireland ETFEIRL1.47M1.84%80.7M USD0.50%$84.99+0.71%
Virtus Biotech Clinical Trials ETFBBC414.64K0.82%50.31M USD0.65%$53.71+0.60%
State Street SPDR S&P International Small Cap ETFGWX316.39K0.03%939.97M USD0.40%$47.03+0.69%
Invesco Nasdaq Biotechnology ETFIBBQ123.7K0.12%98.97M USD0.19%$36.05-0.58%
ProShares Ultra Nasdaq BiotechnologyBIB69.02K0.07%105.96M USD1.19%$120-1.57%
First Trust IPOX Europe Equity Opportunities ETFFPXE16.05K0.32%4.96M USD0.70%$33.1317-0.03%iShares Biotechnology ETFIBBAdvisorShares Psychedelics ETFPSILiShares MSCI Ireland ETFEIRLVirtus Biotech Clinical Trials ETFBBCState Street SPDR S&P International Small Cap ETFGWXInvesco Nasdaq Biotechnology ETFIBBQProShares Ultra Nasdaq BiotechnologyBIBFirst Trust IPOX Europe Equity Opportunities ETFFPXEAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
